Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7442 plus COVID-19 booster vaccination in immunocompromised adults
ISRCTN53507177Phase 2Completed
- Sponsor
- Cardiff University
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of tixagevimab + cilgavimab, elasomeran and tozinameran in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Cardiff University. Primary endpoints: Pharmacokinetics of AZD7442, Safety and tolerability and 2 more. Started Nov 2022; status: completed.
02
Drugs
tixagevimab + cilgavimabelasomerantozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN53507177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN53507177.